Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with PRRT or EBRT in Metastatic Merkel Cell Carcinoma
NCT04261855Phase 2Active, not recruiting
- Start
- Oct 2020
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Merkel cell carcinoma (MCC) comparing Avelumab + EBRT with Avelumab + 177Lu-DOTATATE (2 arms). Primary endpoint: Progression Free Survival at 12 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
avelumablutetium Lu 177 dotatate
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT04261855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261855.